Conversely, although PDE4A expression is also elevated in estrogen receptor-positive and progesterone receptor-positive breast cancer patients, patients with high PDE4A expression have longer progression-free survival (PFS) and overall survival (OS) (57). Here, ESR1 is linked to breast carcinoma.